ArticleClinical rheumatology2007
Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept.
Article in Clinical rheumatology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 45 citations in OpenAlex.
- Article
- Case Report: Disseminated leishmaniasis and rheumatoid arthritis: navigating a clinical conundrum.Frontiers in immunology · 2025Article
- Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression.PLoS neglected tropical diseases · 2019Observational
- Article
- Visceral leishmaniasis in immunosuppressed Caucasian patient.BMJ case reports · 2012Article
- New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.Drug development research · 2011Article
- Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe.Emerging infectious diseases · 2009Review
- Long-term use of an antiinflammatory, curcumin, suppressed type 1 immunity and exacerbated visceral leishmaniasis in a chronic experimental model.Laboratory investigation; a journal of technical methods and pathology · 2008Article
- Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?Clinical rheumatology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral leishmaniasis (VL) is a severe disease that can develop in immunocompromised patients. Antitumor necrosis factor-alpha (TNF-alpha) treatment of rheumatoid arthritis can result in clinical benefits, but with an increased risk of opportunistic infections. Leishmania infection in patients treated with TNF-alpha antagonists is extremely rare; for this reason, we report a patient with VL after etanercept treatment who had an unfavorable outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.